351986-85-1

基本信息
Vacuolin-1 - CAS 351986-85-1 - Calbiochem
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone
(E)-4-(2-(3-iodobenzylidene)hydrazinyl)-6-Morpholino-N,N-diphenyl-1,3,5-triazin-2-aMine
Benzaldehyde, 3-iodo-, 2-[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone
4-[(2E)-2-(3-iodobenzylidene)hydrazinyl]-6-(morpholin-4-yl)-N,N-diphenyl-1,3,5-triazin-2-amine
物理化学性质
沸点 | 719.7±70.0 °C(Predicted) |
密度 | 1.53±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | DMSO:18.33(Max Conc. mg/mL);31.74(Max Conc. mM) DMSO:PBS (pH 7.2) (1:7):0.12(Max Conc. mg/mL);0.21(Max Conc. mM) DMF:3.0(Max Conc. mg/mL);5.2(Max Conc. mM) |
酸度系数(pKa) | 10.74±0.10(Predicted) |
形态 | 白色固体 |
颜色 | White to off-white |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
危险品标志 | Xn |
危险类别码 | 22 |
图谱信息
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone(351986-85-1)核磁图(1HNMR)3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-118630 | 3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone Vacuolin-1 | 351986-85-1 | 5mg | 900元 |
2025/02/08 | HY-118630 | 3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone Vacuolin-1 | 351986-85-1 | 10mg | 1400元 |
2025/02/08 | HY-118630 | 3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone Vacuolin-1 | 351986-85-1 | 50 mg | 2950元 |
常见问题列表
Target | Value |
PIKfyve
() |
Vacuolin-1 (1 μM; Pretreatment 1 hour) blocks ionomycin-induced exocytosis of lysosomes but not of enlargeosomes. It results in vacuolation of lysosomes (A) and complete inhibition of the surface expression of Lamp-1. Vacuolin-1 (1 μM; 20-180 min) disrupts the segregation of inner and limiting membranes characteristic of endosomes and lysosomes. Ultrastructural analysis also shows that vacuolin-1 favours fusion of inner and limiting membranes. Vacuolin-1 (5 or 10 μM; 2 hours) blocks the Ca 2+ -dependent release of β-hexosaminidase from lysosomes. In HeLa cells, ionomycin results in the expected release of 18-20% of lysosomal β-hexosaminidase. But when cells pretreated with vacuolin-1, releases no more β-hexosaminidase compared with cells that are not exposed to ionomycin (4%).